Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 3 , Pages 239-245 , May 2008

Inactivation of p16 by CpG hypermethylation in renal cell carcinoma

  • Marta Vidaurreta

      Affiliations

    • Department of Genomics Laboratory, Hospital Clínico San Carlos, Madrid, Spain
    • ,
  • M. Luisa Maestro, Ph.D.

      Affiliations

    • Department of Genomics Laboratory, Hospital Clínico San Carlos, Madrid, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34-91-3303171; fax: +34-91-3303280.
    • ,
  • M. Teresa Sanz-Casla, M.D.

      Affiliations

    • Department of Genomics Laboratory, Hospital Clínico San Carlos, Madrid, Spain
    • ,
  • Carmen Maestro, Ph.D.

      Affiliations

    • Department of Morphological Science, Complutense University, Madrid, Spain
    • ,
  • Sara Rafael

      Affiliations

    • Department of Genomics Laboratory, Hospital Clínico San Carlos, Madrid, Spain
    • ,
  • Silvia Veganzones

      Affiliations

    • Department of Genomics Laboratory, Hospital Clínico San Carlos, Madrid, Spain
    • ,
  • Jesus Moreno, M.D.

      Affiliations

    • Department of Urology, Hospital Clínico San Carlos, Madrid, Spain
    • ,
  • Julia Blanco, M.D.

      Affiliations

    • Department of Pathology, Hospital Clínico San Carlos, Madrid, Spain
    • ,
  • Angel Silmi, M.D.

      Affiliations

    • Department of Urology, Hospital Clínico San Carlos, Madrid, Spain
    • ,
  • Manuel Arroyo, M.D.

      Affiliations

    • Department of Genomics Laboratory, Hospital Clínico San Carlos, Madrid, Spain

Received 11 December 2006 ,Revised 30 January 2007 ,Accepted 30 January 2007.

References 

  1. Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998;16:1197–1206
  2. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–707
  3. Nobori P, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753–756
  4. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525–4530
  5. Bird A. The essentials of DNA methylation. Cell. 1992;70:5–8
  6. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS-1 in human cancers. Nature Med. 1995;1:686–692
  7. Moch H, Presti JC, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell cancer. Cancer Res. 1996;56:27–30
  8. Schullerus D, Herbers J, Chudek J, et al. Loss of heterozygosity at chromosomes 8p, 9p, and 14p is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol. 1997;183:151–155
  9. Cairns P, Tokino K, Eby Y, et al. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res. 1995;55:224–227
  10. Kinoshita H, Yamada H, Ogawa O, et al. Contribution of chromosome 9p21–22 deletion to the progression of human renal cell carcinoma. Jpn J Cancer Res. 1995;86:795–799
  11. Störkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1 (Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)). Cancer. 1997;80:987–989
  12. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–663
  13. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) Cancer. 1997;80:992–993
  14. Gerardts J, Hruban RH, Schutte M, et al. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of CDKN2/MTS1 gene (A comparison of four commercial antibodies). Appl Immunohistochem Mol Morphol. 2000;8:71–79
  15. Thrash-Bingham CA, Salazar H, Freed J, et al. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res. 1995;55:6189–6195
  16. Kashiwabara K, Oyama T, Sano T, et al. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int J Cancer. 1998;79:215–220
  17. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA. 1994;91:9700–9704
  18. Sakai T, Toguchida J, Ohtani N, et al. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet. 1991;48:880–888
  19. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–3229
  20. Kawada Y, Nakamura M, Ishida E, et al. Aberrations of the p14ARF and p16INK4α genes in renal cell carcinomas. Jpn J Cancer Res. 2001;92:1293–1299
  21. Norrie MWA, Hawkins NJ, Todd AV, et al. Inactivation of p16INK4a by CpG hypermethylation is not a frequent event in colorectal cancer. J Surg Oncol. 2003;84:143–150
  22. Schneider-Stock R, Boltze C, Lasota J, et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol. 2003;21:1688–1697
  23. Qin Y, Liu J, Li B, et al. Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis. World J Gastroenterol. 2004;10:1276–1280
  24. Kaneto H, Sasaki S, Yamamoto H, et al. Detection of hypermethylation of the p16INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C. Gut. 2001;48:372–377
  25. Kinoshita H, Yamada H, Ogawa O, et al. Contribution of chromosome 9p21–22 deletion to the progression of human renal cell carcinoma. Jpn J Cancer Res. 1995;86:795–799
  26. Okamoto A, Demetrick DJ, Spillare EA, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA. 1994;91:11045–11049
  27. Junker K, Weirich G, Amin MB, et al. Genetic subtyping of renal cell carcinoma by comparative genomic hybridization. Recent Results Cancer Res. 2003;162:169–175
  28. Wiencke JK, Zheng S, Lafuente A, et al. Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:501–506
  29. Lengauer C, Kinzler K, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623–627
  30. Toyota M, Ohe-Toyota M, Ahuja N, et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA. 2000;97:710–715
  31. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002;122:1376–1387
  32. Kane MF, Loda M, Gaida GM, et al. Methylation of hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57:808–811
  33. Ward RL, Cheong K, Ku SL, et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol. 2003;21:3729–3736
  34. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69–77
  35. Wright CM, Dent OF, Barker M, et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg. 2000;87:1197–1202

☆ This work is supported by Fundación para la investigación en urología (AEU), Madrid, Spain.

PII: S1078-1439(07)00027-0

doi: 10.1016/j.urolonc.2007.01.018

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 3 , Pages 239-245 , May 2008

Article Tools